The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors

Abstract

The ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp) and ABCG2 are multidrug transporters that confer drug resistance to numerous anti-cancer therapeutics in cell culture. These findings initially created great excitement in the medical oncology community, as inhibitors of these transporters held the promise of overcoming clinical multidrug resistance in cancer patients. However, clinical trials of P-gp and ABCG2 inhibitors in combination with cancer chemotherapeutics have not been successful due, in part, to flawed clinical trial designs resulting from an incomplete molecular understanding of the multifactorial basis of multidrug resistance (MDR) in the cancers examined. The field was also stymied by the lack of high-resolution structural information for P-gp and ABCG2 for use in the rational structure-based drug design of inhibitors. Recent advances in structural biology have led to numerous structures of both ABCG2 and P-gp that elucidated more clearly the mechanism of transport and the polyspecific nature of their substrate and inhibitor binding sites. These data should prove useful helpful for developing even more potent and specific inhibitors of both transporters. As such, although possible pharmacokinetic interactions would need to be evaluated, these inhibitors may show greater effectiveness in overcoming ABC-dependent multidrug resistance in combination with chemotherapeutics in carefully selected subsets of cancers. Another perhaps even more compelling use of these inhibitors may be in reversibly inhibiting endogenously expressed P-gp and ABCG2, which serve a protective role at various blood-tissue barriers. Inhibition of these transporters at sanctuary sites such as the brain and gut could lead to increased penetration by chemotherapeutics used to treat brain cancers or other brain disorders and increased oral bioavailability of these agents, respectively.

Keywords

P-glycoprotein / ABCG2 / ABC transporters / multidrug resistance / inhibitor

References

[1] Lehnert M.Clinical mutidrug resistance in cancer: a multifactorial problem.Eur J Cancer1996;32A:912-20

[2] Saraswathy M.Different strategies to overcome multidrug resistance in cancer.Biotechnol Adv2013;31:1397-407

[3] Gottesman MM,Bates SE.Multidrug resistance in cancer: role of ATP-dependent transporters.Nature Rev Cancer2002;2:48-58

[4] Tarasov VV,Ashraf GM.How cancer cells resist chemotherapy: design and development of drugs targeting protein-protein interactions.Curr Top Med Chem2019;19:394-412

[5] Shankaraiah N,Ommi O.Diverse targeted approaches to battle multidrug resistance in cancer.Curr Med Chem2019;26:7059-80

[6] Bukowski K,Kontek R.Mechanisms of multidrug resistance in cancer chemotherapy.Int J Mol Sci2020;21:3233 PMCID:PMC7247559

[7] Higgins CF.The multidrug resistance P-glycoprotein.Curr Opin Cell Biol1993;5:684-7

[8] Breier A,Seres M,Sulova Z.New insight into p-glycoprotein as a drug target.Anticancer Agents Med Chem2013;13:159-70

[9] Scheper RJ,Scheffer GL,Pinedo HM.Drug-transporter proteins in clinical multidrug resistance.Clin Chim Acta1992;206:25-32

[10] Hrycyna CA.Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance.Semin Cell Dev Biol2001;12:247-56

[11] Borst P.P-glycoprotein ABCB1: a major player in drug handling by mammals.J Clin Invest2013;123:4131-3 PMCID:PMC3784548

[12] Amawi H,Tiwari AK,Shukla S.ABC transporter-mediated multidrug-resistant cancer.Adv Exp Med Biol2019;1141:549-80

[13] Ambudkar SV,Hrycyna CA,Pastan I.Biochemical, cellular, and pharmacological aspects of the multidrug transporter.Annu Rev Pharmacol Toxicol1999;39:361-98

[14] Khalifa MA,Mannel RS,Angros LH.P-glycoprotein as a prognostic indicator in pre- and postchemotherapy ovarian adenocarcinoma.Int J Gynecol Pathol1997;16:69-75

[15] Soini Y,Raunio H.Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.J Clin Pathol1996;49:470-3 PMCID:PMC500536

[16] Xu D,Pisa P.Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.Br J Haematol1996;92:847-54

[17] Robey RW,Hall MD,Bates SE.Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[18] Hipfner DR,Cole SP.Structural, mechanistic and clinical aspects of MRP1.Biochim Biophys Acta1999;1461:359-76

[19] Binkhathlan Z.P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.Curr Cancer Drug Targets2013;13:326-46

[20] Darby RA,McMahon RM.P-glycoprotein inhibition: the past, the present and the future.Curr Drug Metab2011;12:722-31

[21] Dong J,Zhang WD.Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update.Drug Resist Updat2020;49:100681

[22] Krishna R.Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.Curr Med Chem Anti-Canc Agents2001;1:163-74

[23] Palmeira A,Vasconcelos MH.Three decades of P-gp inhibitors: skimming through several generations and scaffolds.Curr Med Chem2012;19:1946-2025

[24] Jaramillo AC,Cloos J,Peters GJ.How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?.Cancer Drug Resistance2018;1:6-29

[25] Sharom FJ.ABC multidrug transporters: structure, function and role in chemoresistance.Pharmacogenomics2008;9:105-27

[26] Amiri-Kordestani L,Kurdziel K,Bates SE.Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Drug Resist Updat2012;15:50-61 PMCID:PMC3680361

[27] Leonard GD,Bates SE.The role of ABC transporters in clinical practice.Oncologist2003;8:411-24

[28] Borst P.Looking back at multidrug resistance (MDR) research and ten mistakes to be avoided when writing about ABC transporters in MDR.FEBS Lett2020;594:4001-11

[29] Szakacs G,Ludwig JA,Gottesman MM.Targeting multidrug resistance in cancer.Nat Rev Drug Discov2006;5:219-34

[30] Bradshaw DM.Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.J Clin Oncol1998;16:3674-90

[31] Ferry DR,Kerr DJ.Clinical trials of P-glycoprotein reversal in solid tumours.Eur J Cancer1996;32A:1070-81

[32] Fisher GA.Clinical studies with modulators of multidrug resistance.Hematol Oncol Clin North Am1995;9:363-82

[33] Libby E.Dismounting the MDR horse.Blood2010;116:4037-8

[34] Thomas C.Structural and mechanistic principles of ABC transporters.Annu Rev Biochem2020;89:605-36

[35] Niazi M,Najafi Hajivar S.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.Expert Opin Drug Metab Toxicol2016;12:1021-33

[36] Schinkel AH.P-Glycoprotein, a gatekeeper in the blood-brain barrier.Adv Drug Deliv Rev1999;36:179-94

[37] Schinkel AH,Mol CA.P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.J Clin Invest1996;97:2517-24 PMCID:PMC507337

[38] Dietrich CG,Oude Elferink RP.ABC of oral bioavailability: transporters as gatekeepers in the gut.Gut2003;52:1788-95 PMCID:PMC1773875

[39] Goldstein MN,Journey LJ.In vitro studies with HeLa cell line sensitive and resistant to actinomycin D.Ann N Y Acad Sci1960;89:474-83

[40] Biedler JL.Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.Cancer Res1970;30:1174-84

[41] Danø K.Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.Biochem Biophys Acta1973;323:466-83

[42] Juliano RL.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.Biochim Biophys Acta1976;455:152-62

[43] Riordan JR.Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability.J Biol Chem1979;254:12701-5

[44] Gros P,Roninson IB,Housman DE.Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells.Proc Natl Acad Sci U S A1986;83:337-41 PMCID:PMC322853

[45] Roninson IB,Choi K.Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.Proc Natl Acad Sci U S A1986;83:4538-52 PMCID:PMC323769

[46] Ueda K,Gottesman MM.The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein.Biochem Biophys Res Comm1986;141:956-62

[47] Dean M,Chimini G.The human ATP-binding cassette (ABC) transporter superfamily.J Lipid Res2001;42:1007-17

[48] Higgins CF.ABC transporters: from microorganisms to man.Annu Rev Cell Biol1992;8:67-113

[49] Ouellette M,Papadopoulou B.Microbial multidrug-resistance ABC transporters.Trends Microbiol1994;2:407-11

[50] Theodoulou FL.Plant ABC transporters.Biochim Biophys Acta2000;1465:79-103

[51] Allikmets R,Hutchinson A.Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database.Hum Mol Genet1996;5:1649-55

[52] Balzi E.Yeast multidrug resistance: the PDR network.J Bioenerg Biomembr1995;27:71-6

[53] Allikmets R,Hutchinson A,Dean M.A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.Cancer Res1998;58:5337-9

[54] Doyle LA,Abruzzo LV.A multidrug resistance transporter from human MCF-7 breast cancer cells.Proc Natl Acad Sci U S A1998;95:15665-70 PMCID:PMC28101

[55] Miyake K,Litman T.Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.Cancer Res1999;59:8-13

[56] Dean M.Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates.Annu Rev Genomics Hum Genet2005;6:123-42

[57] Thomas H.Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.Cancer Control2003;10:159-65

[58] Robey RW,Amiri-Kordestani L.ABC transporters: unvalidated therapeutic targets in cancer and the CNS.Anticancer Agents Med Chem2010;10:625-33 PMCID:PMC3119022

[59] Patch AM,Etemadmoghadam D.Whole-genome characterization of chemoresistant ovarian cancer.Nature2015;521:489-94

[60] da Silveira Júnior LS,Jardim da Silva AS.P-glycoprotein and multidrug resistance-associated protein-1 expression in acute myeloid leukemia: biological and prognosis implications.Int J Lab Hematol2020;42:594-603

[61] Hendrikse NH,de Vries EG.Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.Br J Pharmacol1998;124:1413-8 PMCID:PMC1565536

[62] Syvanen S.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.ACS Chem Neurosci2013;4:225-37 PMCID:PMC3582299

[63] Begley DJ.ABC transporters and the blood-brain barrier.Curr Pharm Des2004;10:1295-312

[64] Cardon-Cardo C,Casals D.Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.Proc Natl Acad Sci U S A1989;86:695-8 PMCID:PMC286540

[65] Takano M,Murakami T.Expression and function of efflux drug transporters in the intestine.Pharmacol Ther2006;109:137-61

[66] Gottesman MM,Schoenlein PV,Pastan I.Genetic analysis of the multidrug transporter.Annu Rev Genet1995;29:607-49

[67] AL. Blood-brain barrier P-glycoprotein function in neurodegenerative disease.Curr Pharm Des2011;17:2771-7

[68] Loscher W.Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.NeuroRx2005;2:86-98 PMCID:PMC539326

[69] Vlaming ML,Schinkel AH.Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice.Adv Drug Deliv Rev2009;61:14-25

[70] Schinkel AH,Wagenaar E.Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.Proc Natl Acad Sci U S A1997;94:4028-33 PMCID:PMC20562

[71] Schinkel AH,Wagenaar E,Smit JJ.Multidrug resistance and the role of P-glycoprotein knockout mice.Eur J Cancer1995;31A:1295-8

[72] Schinkel AH,van Tellingen O.Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.Cell1994;77:491-502

[73] Schinkel AH,van Deemter L,Borst P.Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.J Clin Invest1995;96:1698-705 PMCID:PMC185805

[74] Breedveld P,Cipriani G.The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.Cancer Res2005;65:2577-82

[75] Jonker JW,Wagenaar E.The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.Proc Natl Acad Sci U S A2002;99:15649-54 PMCID:PMC137771

[76] Zhou S,Barnes Y,Schuetz JD.Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo.Proc Natl Acad Sci U S A2002;99:12339-44 PMCID:PMC129446

[77] Schinkel AH.Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.Adv Drug Deliv Rev2003;55:3-29

[78] Oostendorp RL,Beijnen JH,Schellens JH.The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.Invest New Drugs2009;27:31-40

[79] Fellner S,Miller DS.Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.J Clin Invest2002;110:1309-18 PMCID:PMC151606

[80] Lagas JS,Sparidans RW,Beijnen JH.Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.Mol Cancer Ther2010;9:319-26

[81] Durmus S,Wagenaar E,Schinkel AH.Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.Mol Pharm2012;9:3236-45

[82] Kort A,Wagenaar E,Schinkel AH.Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).Pharmacol Res2015;102:200-7

[83] Tang SC,Lankheet NA.Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.Int J Cancer2012;130:223-33

[84] Bohn K,Chmielewski J.Dual modulation of human P-glycoprotein and ABCG2 with prodrug dimers of the atypical antipsychotic agent paliperidone in a model of the blood-brain barrier.Mol Pharm2017;14:1107-19

[85] Gu X,Peng H,Zhang Y.Bifendate-chalcone hybrids: a new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.Biochem Biophys Res Commun2014;455:318-22

[86] Namanja-Magliano HA,Agrawal N,Hrycyna CA.Dual inhibitors of the human blood-brain barrier drug efflux transporters P-glycoprotein and ABCG2 based on the antiviral azidothymidine.Bioorg Med Chem2017;25:5128-32

[87] Berggren S,Wollnitz N.Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine.Mol Pharm2007;4:252-7

[88] Maliepaard M,Faneyte IF.Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.Cancer Res2001;61:3458-64

[89] Thiebaut F,Hamada H,Pastan I.Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues.Proc Natl Acad Sci U S A1987;84:7735-8 PMCID:PMC299375

[90] Lepper ER,Verweij J,Figg WD.Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.Pharmacogenomics2005;6:115-38

[91] Sparreboom A,Ando Y,Figg WD.Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.Drug Resist Updat2003;6:71-84

[92] Malingré MM,Rosing H.Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.Br J Cancer2001;84:42-7 PMCID:PMC2363627

[93] Meerum Terwogt JM,Beijnen JH.Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.Clin Cancer Res1999;5:3379-84

[94] Jonker JW,Brinkhuis RF.Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.J Natl Cancer Inst2000;92:1651-6

[95] Sesink AL,de Boer VC,Schellens JH et al.Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides.Mol Pharmacol2005;67:1999-2006

[96] Zaher H,Palandra J,Yu L.Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.Mol Pharm2006;3:55-61

[97] Gottesman MM.Biochemistry of multidrug resistance mediated by the multidrug transporter.Annu Rev Biochem1993;62:385-427

[98] Borst P.Mammalian ABC transporters in health and disease.Annu Rev Biochem2002;71:537-92

[99] Rees DC,Lewinson O.ABC transporters: the power to change.Nat Rev Mol Cell Biol2009;10:218-27 PMCID:PMC2830722

[100] Hrycyna CA,Germann UA,Pastan I.Both ATP sites of human P-glycoprotein are essential but not symmetric.Biochemistry1999;38:13887-99

[101] Julien M.Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity.Biochemistry2000;39:4559-68

[102] Loo TW,Clarke DM.Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains.J Biol Chem2003;278:1575-8

[103] Ambudkar SV,Sauna ZE.P-glycoprotein: from genomics to mechanism.Oncogene2003;22:7468-85

[104] Sauna ZE.Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes.J Biol Chem2001;276:11653-61

[105] Ramachandra M,Chen D.Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.Biochemistry1998;37:5010-9

[106] Sauna ZE.Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.Proc Natl Acad Sci U S A2000;97:2515-20 PMCID:PMC15960

[107] Senior AE,Urbatsch IL.The catalytic cycle of P-glycoprotein.FEBS Lett1995;377:285-9

[108] Urbatsch IL,Bhagat S.Both P-glycoprotein nucleotide-binding sites are catalytically active.J Biol Chem1995;270:26956-61

[109] Urbatsch IL,Weber J.P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.J Biol Chem1995;270:19383-90

[110] Esser L,Pluchino KM.Structures of the multidrug transporter P-glycoprotein reveal asymmetric ATP binding and the mechanism of polyspecificity.J Biol Chem2017;292:446-61 PMCID:PMC5241723

[111] Kim Y.Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation.Science2018;359:915-9

[112] Nosol K,Irobalieva RN.Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1.Proc Natl Acad Sci U S A2020;117:26245-53 PMCID:PMC7585025

[113] Alam A,Broude E,Locher KP.Structural insight into substrate and inhibitor discrimination by human P-glycoprotein.Science2019;363:753-6 PMCID:PMC6800160

[114] Alam A,Kowal J.Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1.Proc Natl Acad Sci U S A2018;115:E1973-E82 PMCID:PMC5834697

[115] Thonghin N,Barbieri A,Siebert A.Novel features in the structure of P-glycoprotein (ABCB1) in the post-hydrolytic state as determined at 7.9 Å resolution.BMC Struct Biol2018;18:17 PMCID:PMC6293506

[116] Nicklisch SC,McGrath AP.Global marine pollutants inhibit P-glycoprotein: Environmental levels, inhibitory effects, and cocrystal structure.Sci Adv2016;2:e1600001 PMCID:PMC4846432

[117] Szewczyk P,McGrath AP.Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein.Acta Crystallogr D Biol Crystallogr2015;71:732-41 PMCID:PMC4356375

[118] Ward AB,Grimard V.Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain.Proc Natl Acad Sci U S A2013;110:13386-91 PMCID:PMC3746859

[119] Le CA,Aller SG.Structural definition of polyspecific compensatory ligand recognition by P-glycoprotein.IUCrJ2020;7:663-72 PMCID:PMC7340268

[120] Li J,Aller SG.Refined structures of mouse P-glycoprotein.Protein Sci2014;23:34-46 PMCID:PMC3892297

[121] Jin MS,Zhang Q.Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans.Nature2012;490:566-9 PMCID:PMC3482266

[122] Hrycyna CA,Ambudkar SV.Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites.J Biol Chem1998;273:16631-4

[123] Dastvan R,Peskova YB,McHaourab HS.Mechanism of allosteric modulation of P-glycoprotein by transport substrates and inhibitors.Science2019;364:689-92 PMCID:PMC6890515

[124] Jackson SM,Kowal J.Structural basis of small-molecule inhibition of human multidrug transporter ABCG2.Nat Struct Mol Biol2018;25:333-40

[125] Manolaridis I,Taylor NMI,Stahlberg H.Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.Nature2018;563:426-30 PMCID:PMC6379061

[126] Taylor NMI,Jackson SM,Stahlberg H.Structure of the human multidrug transporter ABCG2.Nature2017;546:504-9

[127] Orlando BJ.ABCG2 transports anticancer drugs via a closed-to-open switch.Nat Commun2020;11:2264 PMCID:PMC7210939

[128] Litman T,Stein WD.From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.Cell Mol Life Sci2001;58:931-59

[129] Robey RW,Polgar O.ABCG2: a perspective.Adv Drug Deliv Rev2009;61:3-13 PMCID:PMC3105088

[130] Chufan EE,Ambudkar SV.Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies.Adv Cancer Res2015;125:71-96 PMCID:PMC7709800

[131] Dey S,Pastan I,Ambudkar SV.Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.Proc Natl Acad Sci U S A1997;94:10594-9 PMCID:PMC23414

[132] Loo TW.Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques.Biochim Biophys Acta1999;1461:315-25

[133] Loo TW.The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface.J Biol Chem1999;274:24759-65

[134] Loo TW.Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil.J Biol Chem2001;276:14972-9

[135] Loo TW.Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein.J Biol Chem2002;277:44332-8

[136] Martin C,Higgins CF,Charlton P.Communication between multiple drug binding sites on P-glycoprotein.Mol Pharmacol2000;58:624-32

[137] Mittra R,Subramanian N.Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein.Biochem Pharmacol2017;123:19-28

[138] Shapiro AB,Ling V.P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer.Eur J Biochem1997;250:115-21

[139] Shapiro AB,Lam P.Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.Eur J Biochem1999;259:841-50

[140] Bruggemann EP,Gottesman MM.Characterization of the azidopine and vinblastine binding site of P-glycoprotein.J Biol Chem1992;267:21020-6

[141] Bruggemann EP,Gottesman MM.Two different regions of P-glycoprotein are photoaffinity labeled by azidopine.J Biol Chem1989;264:15483-8

[142] Sauna ZE,Turner TM.Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.Biochemistry2004;43:2262-71

[143] Chmielewski J.Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp.Ther Deliv2012;3:689-92

[144] Emmert D,Ward D.Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier.ACS Chem Neurosci2014;5:305-17 PMCID:PMC3990950

[145] Kuriakose J,Chmielewski J.Click chemistry-derived bivalent quinine inhibitors of P-glycoprotein-mediated cellular efflux.Bioorg Med Chem Lett2012;22:4410-2

[146] Namanja HA,Davis DA.Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers.J Am Chem Soc2012;134:2976-80 PMCID:PMC3262104

[147] Namanja HA,Hrycyna CA.Homodimers of the antiviral abacavir as modulators of P-glycoprotein transport in cell culture: Probing Tether Length.Medchemcomm2013;4:10.1039/C3MD00196B PMCID:PMC3833348

[148] Namanja HA,Pires MM,Chmielewski J.Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer.Biochem Biophys Res Commun2009;388:672-6 PMCID:PMC2764298

[149] Pires MM,Hrycyna CA.Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.Mol Pharmacol2009;75:92-100 PMCID:PMC2685053

[150] Pires MM,Chmielewski J.Bivalent probes of the human multidrug transporter P-glycoprotein.Biochemistry2006;45:11695-702

[151] Chan KF,Burkett BA,Chow LM.Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.J Med Chem2006;49:6742-59

[152] Chan KF,Chow TW.Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships.ChemMedChem2009;4:594-614

[153] Cui J,Chow LMC.Flavonoids as P-gp inhibitors: a systematic review of SARs.Curr Med Chem2019;26:4799-831

[154] Zhu X,Chan KF.Triazole bridged flavonoid dimers as potent, nontoxic, and highly selective breast cancer resistance protein (BCRP/ABCG2) inhibitors.J Med Chem2019;62:8578-608

[155] Amin ML.P-glycoprotein inhibition for optimal drug delivery.Drug Target Insights2013;7:27-34 PMCID:PMC3762612

[156] Tamaki A,Szakacs G,Bates SE.The controversial role of ABC transporters in clinical oncology.Essays Biochem2011;50:209-32 PMCID:PMC6944313

[157] Leonard GD,Bates SE.ABC transporters and inhibitors: new targets, new agents.Curr Opin Investig Drugs2002;3:1652-9

[158] Pajic M,Kersbergen A.Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.Cancer Res2009;69:6396-404

[159] Stewart DJ.Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol2010;75:173-234 PMCID:PMC2888634

[160] Kannan P,Shukla S.The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).ACS Chem Neurosci2011;2:82-9 PMCID:PMC3369725

[161] Kühnle M,Müller C.Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.J Med Chem2009;52:1190-7

[162] Karthikeyan S.Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance.Anticancer Agents Med Chem2015;15:605-15

[163] Lopes-Rodrigues V,Vasconcelos MH.Curcumin as a modulator of P-glycoprotein in cancer: challenges and perspectives.Pharmaceuticals (Basel)2016;9:71 PMCID:PMC5198046

[164] Kumar KK,Gnananath K,Sujatha S.Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats.Eur J Drug Metab Pharmacokinet2015;40:267-76

[165] Kim MK,Choo H.Quercetin-glutamic acid conjugate with a non-hydrolysable linker; a novel scaffold for multidrug resistance reversal agents through inhibition of P-glycoprotein.Bioorg Med Chem2017;25:1219-26

[166] El-Readi MZ,Abdelghany AA,Efferth T.Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes.Phytomedicine2019;55:269-81

[167] Sun JH,Bai EH.Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro.Nanotechnology2019;30:085101

[168] Xue C,Liu Q.Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.Tumour Biol2016;37:8587-97

[169] Tajima Y,Tamura A.Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1.Phytomedicine2014;21:323-32

[170] Zhai Q,Li C.Inhibition of breast cancer resistance protein (BCRP) by Ko143 can affect pharmacokinetics of enrofloxacin in exopalaemon carinicauda.Journal of Ocean University of China volume2020;19:1124

[171] Woehlecke H,Herrmann A.Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.Int J Cancer2003;107:721-8

[172] Wang Y,Shang D.Interactions between artemisinin derivatives and P-glycoprotein.Phytomedicine2019;60:152998

[173] Xu W,Chen S.Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.Eur J Pharmacol2020;881:173232

[174] Lopez D.Marine natural products with P-glycoprotein inhibitor properties.Mar Drugs2014;12:525-46 PMCID:PMC3917285

[175] Lai JI,Chen MH,Chang PM.Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics.Front Oncol2020;10:561936 PMCID:PMC7704056

[176] Mollazadeh S,Hadizadeh F,Arabzadeh S.Structural and functional aspects of P-glycoprotein and its inhibitors.Life Sci2018;214:118-23

[177] Juvale K.Design of inhibitors of BCRP/ABCG2.Future Med Chem2015;7:1521-7

[178] Wiese M.BCRP/ABCG2 inhibitors: a patent review (2009-present).Expert Opin Ther Pat2015;25:1229-37

[179] Leopoldo M,Contino M,Luurtsema G.An updated patent review on P-glycoprotein inhibitors (2011-2018).Expert Opin Ther Pat2019;29:455-61

[180] Toyoda Y,Suzuki H.Inhibitors of human ABCG2: from technical background to recent updates with clinical implications.Front Pharmacol2019;10:208 PMCID:PMC6411714

[181] Laiolo J,Vera DMA.Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.ACS Med Chem Lett2018;9:1186-92 PMCID:PMC6295845

[182] Sachs J,Weber A.Selective inhibition of P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy.J Nat Med2019;73:226-35

[183] Chae SW,Park JH,Na Y.Intestinal P-glycoprotein inhibitors, benzoxanthone analogues.J Pharm Pharmacol2018;70:234-41

[184] Chen CY,Lin HC,Hung CC.Synthesis and bioevaluation of novel benzodipyranone derivatives as P-glycoprotein inhibitors for multidrug resistance reversal agents.Eur J Med Chem2016;118:219-29

[185] D Dinić J,Jovanović M.Novel heat shock protein 90 inhibitors suppress P-glycoprotein activity and overcome multidrug resistance in cancer cells.Int J Mol Sci2019;20:4575 PMCID:PMC6770006

[186] Hemmer M,Simon I.Discovery of substituted 1,4-dihydroquinolines as novel promising class of P-glycoprotein inhibitors: first structure-activity relationships and bioanalytical studies.Bioorg Med Chem Lett2015;25:3005-8

[187] Mollazadeh S,Kalalinia F,Hadizadeh F.Synthesis, in silico and in vitro studies of new 1,4-dihydropiridine derivatives for antitumor and P-glycoprotein inhibitory activity.Bioorg Chem2019;91:103156

[188] Ranjbar S,Moreno A.5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.Toxicol Appl Pharmacol2019;362:136-49

[189] Liu CP,Zhao JX.Dysoxylactam A: a macrocyclolipopeptide reverses P-glycoprotein-mediated multidrug resistance in cancer cells.J Am Chem Soc2019;141:6812-6

[190] Singh S,Chufan EE.Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.J Med Chem2014;57:4058-72 PMCID:PMC4032198

[191] de Ravel MR,Melikian M.Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells.J Med Chem2015;58:1832-45

[192] Rocheblave L,Monniot E.Deoxycholic acid derivatives as inhibitors of P-glycoprotein-mediated multidrug efflux.Steroids2016;116:5-12

[193] Zeino M,Zehl M,Kopp B.Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids.Biochem Pharmacol2015;93:11-24

[194] Bonandi E,Fumagalli G,Rastelli G.The 1,2,3-triazole ring as a bioisostere in medicinal chemistry.Drug Discov Today2017;22:1572-81

[195] Jekerle V,Scollard DA.In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.Int J Cancer2006;119:414-22

[196] Mistry P,Dangerfield W.In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.Cancer Res2001;61:749-58

[197] Chan KF,Kan JW,Chow LM.Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.J Med Chem2012;55:1999-2014

[198] Wang JS,Markowitz JS,DeVane CL.Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.Psychopharmacology (Berl)2006;187:415-23

[199] Munic V,Mikac L.Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays.Eur J Pharm Sci2010;41:86-95

[200] Domvri K,Zogas N.Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.J Cancer2017;8:3648-56 PMCID:PMC5688917

[201] Krchniakova M,Neradil J,Veselska R.Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration.Int J Mol Sci2020;21:3157 PMCID:PMC7247577

[202] Agarwal S,Gallardo JL,Elmquist WF.Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.J Pharmacol Exp Ther2010;334:147-55 PMCID:PMC2912048

[203] Chen Y,Shaik NM,Yang Z.P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.J Pharmacol Exp Ther2009;330:956-63

[204] Shukla S,Ambudkar SV.Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2.Leukemia2008;22:445-7

[205] Traxl A,Mairinger S.Breast cancer resistance protein and P-glycoprotein influence in vivo disposition of 11C-Erlotinib.J Nucl Med2015;56:1930-6

[206] Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.Pharmacol Res2017;120:43-50

[207] Zhou ZY,Yang QJ.Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.Toxicol Lett2016;259:124-32

[208] Durmus S,van Esch A,Beijnen JH.Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).Pharm Res2015;32:37-46

[209] Vaidyanathan A,Gannon AL.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Br J Cancer2016;115:431-41 PMCID:PMC4985349

[210] de Gooijer MC,Thota N.P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.Invest New Drugs2015;33:1012-9

[211] Wu T,To KKW.Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.Biochem Pharmacol2017;124:29-42

[212] Gallo JM,Guo P,Ma J.The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice.Cancer Res2003;63:5114-7

[213] Tang SC,Cheung KL.P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (Jevtana) in mice.Mol Pharm2015;12:3714-23

[214] Fisher M,Van Aerschot A.Inhibition of MDR1 expression with altritol-modified siRNAs.Nucleic Acids Res2007;35:1064-74 PMCID:PMC1851637

[215] Li H,Li T.Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.Hepatogastroenterology2012;59:2238-42

[216] Perez J,Rigal C,Rousseau R.Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines.Anticancer Res2011;31:2813-20

[217] Hong L,Zhang H.The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma.Ann Surg2010;251:1056-63

[218] Bao L,Mehra S,Moroz K.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.Am J Pathol2012;180:2490-503 PMCID:PMC3378910

[219] Xie Y,Deng X,Chen Y.MicroRNA-298 reverses multidrug resistance to antiepileptic drugs by suppressing MDR1/P-gp expression in vitro.Front Neurosci2018;12:602 PMCID:PMC6121027

[220] Nadali F,Alimoghaddam K.Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells.Hematology2007;12:393-401

[221] Rittierodt M,Harada K.Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA.Pathobiology2004;71:123-8

[222] White MK.CRISPR/Cas9 and cancer targets: future possibilities and present challenges.Oncotarget2016;7:12305-17 PMCID:PMC4914286

[223] Norouzi-Barough L,Salehi R,Moghbelinejad S.CRISPR/Cas9, a new approach to successful knockdown of ABCB1/P-glycoprotein and reversal of chemosensitivity in human epithelial ovarian cancer cell line.Iran J Basic Med Sci2018;21:181-7 PMCID:PMC5811757

[224] Simoff I,Backlund M.Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9.J Pharm Sci2016;105:1017-21

[225] Broxterman HJ,Schuurhuis GJ,Pinedo HM.Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.Biochem Pharmacol1988;37:2389-93

[226] Pearson JW,Volker K.In vivo administration of MRK-16 monoclonal antibody reverses drug resistance in a human colon cancer xenograft expressin the MDR1 cDNA.J Natl Cancer Inst1991;83:1386-91

[227] Tsuruo T,Sato S.Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies.Jpn J Cancer Res1989;80:627-31 PMCID:PMC5917818

[228] Hamada H.Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.Proc Natl Acad Sci U S A1986;83:7785-9 PMCID:PMC386806

[229] Naito M,Kuroko C.Enhancement of cellular accumulation of cyclosporine by Anti-P-Glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance.J Nat Cancer Inst1993;85:311-6

[230] Pearson JW,Volker K.Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody.J Natl Cancer Inst1991;83:1386-91

[231] Mechetner EB.Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.Proc Natl Acad Sci U S A1992;89:5824-8 PMCID:PMC402110

[232] Goda K,Bacsó Z.Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.J Pharmacol Exp Ther2007;320:81-8

[233] Druley TE,Roninson IB.Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity.Biochemistry2001;40:4312-22

[234] Mechetner EB,Morse BS.P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.Proc Natl Acad Sci U S A1997;94:12908-13 PMCID:PMC24237

[235] Ritchie TK,Atkins WM.Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.J Biol Chem2011;286:39489-96 PMCID:PMC3234772